There are a number of exciting technological advances that could change diabetes care as we know it, such as improved continuous glucose monitors and convenient decision support tools, said Robert Gabbay, MD, PhD, chief medical officer of the Joslin Diabetes Center.
There are a number of exciting technological advances that could change diabetes care as we know it, such as improved continuous glucose monitors and convenient decision support tools, said Robert Gabbay, MD, PhD, chief medical officer of the Joslin Diabetes Center.
Transcript (slightly modified)
What developments in diabetes technology will we see in the next year after the American Diabetes Association Scientific Sessions?
Diabetes technology is about to explode in terms of its impact on diabetes care, and I think there are a few different ways that’s going to happen. One is in the realm of continuous glucose monitors; they’re about to become cheaper, more accurate, and a new one on the market that doesn’t require calibration, ultimately has the potential if it’s inexpensive enough to replace blood glucose monitoring as we know it with a lot more information. That added information could be used to help drive better outcomes for patients with diabetes, so that’s one big exciting area of technology.
The second one I’ll mention is using that continuous glucose data to drive insulin pump changes, and the first step of that is the Medtronic 670G, which will allow titration of insulin through the pump overnight to maintain near-normal glucose levels. It’ll be a self-regulating system, the first time that’s really been available. Initially it’ll be only for a small subset of people, mostly those with type 1 and some with type 2 that are on insulin pumps, but I think that technology will continue to evolve and improve and become more widely available.
The third area that I’ll mention that I think is also very exciting is the decision support tools and the ability to provide real-time information to patients, but also potentially to providers on how to better manage patients, and for patients how to better care for themselves. Being able to capture all the information—glucose levels, activity levels through step counting and other mechanisms, and dietary information—all on somebody’s smartphone to help guide and coach them towards a better lifestyle could be very effective. Similarly, that information transmitted to providers in an intelligible and actionable way could also drive better care.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Exploring Pharmaceutical Innovations, Trust, and Access With CVS Health's CMO
July 11th 2024On this episode of Managed Care Cast, we're talking with the chief medical officer of CVS Health about recent pharmaceutical innovations, patient-provider relationships, and strategies to reduce drug costs.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More